In contrast, SPAG6 demonstrated decreased expression in lung cancer (Altenberger et al., 2017; Wu et al., 2022) and bladder cancer (Kitchen et al., 2015) owing to high methylation of its promoter (Altenberger et al., 2017), and was considered a tumor suppressor gene in these cancers. Here, SPAG6 is linked to urinary bladder cancer.